#USA #San Diego #ClassAction #ImmunityBio #IBRX

ImmunityBio Class Action Lawsuit: Key Details for Investors

As investors brace for potential losses in ImmunityBio, Inc. (NASDAQ: IBRX), Robbins Geller Rudman & Dowd LLP has announced a significant opportunity ahead of the investor deadline on May 26, 2026. Investors who acquired ImmunityBio's publicly traded securities between January 19, 2026, and March 24, 2026, are eligible to seek appointment as the lead plaintiff in a class action lawsuit against the company.

Background on ImmunityBio

ImmunityBio is at the forefront of developing innovative immunotherapies, with a focus on their lead product, Anktiva. However, the company has recently come under scrutiny due to allegations of misleading information regarding the efficacy of their treatment for bladder cancer. The complaints suggest that claims regarding Anktiva's ability to keep patients cancer-free long-term were unproven, leading to significant investor losses when these elements became publicly known.

Allegations in the Class Action

According to the plaintiffs, ImmunityBio and its Executive Chairman, Dr. Patrick Soon-Shiong, made several representations during the class period that were potentially misleading. These include:

• - Claims that Anktiva acts as a cancer vaccine without substantial evidence.
• - Statements suggesting that the treatment results in long-term cancer-free patients, which have not been demonstrated.

Moreover, a critical turning point occurred when the U.S. Food and Drug Administration (FDA) issued a warning letter that raised concerns about a TV advertisement and podcasts promoting Anktiva. The FDA described these communications as misleading, hinting that they could create the impression that Anktiva could cure all types of cancer. Following this public revelation, ImmunityBio’s stock saw a drastic decline of 21%, devastating many investors.

How to Participate in the Class Action

For investors interested in taking part in this class action lawsuit, the Private Securities Litigation Reform Act of 1995 allows investors with financial interests to step forward as lead plaintiffs. The lead plaintiff plays a crucial role, as they represent the collective interests of all impacted investors. Furthermore, regardless of their status as lead plaintiff, all investors still retain the right to share in any financial recovery that may arise from the case, should it proceed successfully.

To apply to be a lead plaintiff or for more information, investors should provide their details on the designated firm’s case page or contact attorneys Ken Dolitsky or Michael Albert directly.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is noted for its expertise in securities litigation and has been a leader in recovering substantial funds for investors in past cases. With a strong track record, including recovering over $8.4 billion in the past five years, the firm remains committed to advocating for shareholders’ rights.

This situation is a poignant reminder of the risks involved in investment and the importance of due diligence and obtaining reliable information. If you are affected by this situation, ensure you take action before the May 26 deadline to protect your legal rights and explore potential recovery avenues.

For further details on the class action, visit their webpage or contact the law firm directly. Your participation could play an essential role in the outcome of this significant case against ImmunityBio.